Requirements Federated Learning and mUlti-party computation Techniques for prostatE cancer
0.1.0 - ci-build
Requirements Federated Learning and mUlti-party computation Techniques for prostatE cancer, published by HL7 Europe. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/flute-requirements/ and changes regularly. See the Directory of published versions
<ResearchStudy xmlns="http://hl7.org/fhir">
<id value="RS-ResearchStudyFLUTE"/>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ResearchStudy RS-ResearchStudyFLUTE</b></p><a name="RS-ResearchStudyFLUTE"> </a><a name="hcRS-ResearchStudyFLUTE"> </a><blockquote><p><b>EXT-Datamart</b></p><ul><li>variable: <a href="EvidenceVariable-EV-EvidenceVariableFLUTEGroup.html">EvidenceVariable Group of EvidenceVariables for the FLUTE ResearchStudy</a></li></ul></blockquote><p><b>url</b>: <a href="https://flute.com/ResearchStudy/RS-ResearchStudyFLUTE">https://flute.com/ResearchStudy/RS-ResearchStudyFLUTE</a></p><p><b>name</b>: FLUTEResearchStudy</p><p><b>title</b>: FLUTE Research Study</p><p><b>status</b>: Active</p><p><b>primaryPurposeType</b>: <span title="Codes:{http://hl7.org/fhir/research-study-prim-purp-type treatment}">Treatment</span></p><p><b>phase</b>: <span title="Codes:{https://flute.com/CodeSystem/COS-ResearchStudyPhase initial}">Initial Phase</span></p><p><b>studyDesign</b>: <span title="Codes:{http://hl7.org/fhir/study-design SEVCO:01001}">Interventional research</span></p><p><b>keyword</b>: <span title="Codes:">Prostatic Cancer</span>, <span title="Codes:">Family History</span>, <span title="Codes:">Prostatic-Specific Antigen</span>, <span title="Codes:">DRE</span></p><p><b>description</b>: </p><div><p>A study to evaluate the impact of family history on prostatic cancer follow-up criterias, such as level of prostatic-specific antigen and DRE.</p>
</div><p><b>period</b>: 2025-01-01 --> 2025-12-31</p><h3>AssociatedParties</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Name</b></td><td><b>Role</b></td></tr><tr><td style="display: none">*</td><td>Research Coordinator</td><td><span title="Codes:{http://hl7.org/fhir/research-study-party-role general-contact}">general-contact</span></td></tr></table><h3>Recruitments</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Eligibility</b></td></tr><tr><td style="display: none">*</td><td><a href="EvidenceVariable-EV-InclusionCriteriaFLUTE.html">EvidenceVariable Inclusion Variable for FLUTE Study</a></td></tr></table></div>
</text>
<extension url="https://www.isis.com/StructureDefinition/EXT-Datamart">
<extension url="variable">
<valueReference>🔗
<reference value="EvidenceVariable/EV-EvidenceVariableFLUTEGroup"/>
<identifier>
<system value="https://flute.com/EvidenceVariable"/>
<value value="EvidenceVariableFLUTEGroup"/>
</identifier>
</valueReference>
</extension>
</extension>
<url value="https://flute.com/ResearchStudy/RS-ResearchStudyFLUTE"/>
<name value="FLUTEResearchStudy"/>
<title value="FLUTE Research Study"/>
<status value="active"/>
<primaryPurposeType>
<coding>
<system value="http://hl7.org/fhir/research-study-prim-purp-type"/>
<code value="treatment"/>
<display value="Treatment"/>
</coding>
</primaryPurposeType>
<phase>
<coding>
<system value="https://flute.com/CodeSystem/COS-ResearchStudyPhase"/>
<code value="initial"/>
<display value="Initial Phase"/>
</coding>
</phase>
<studyDesign>
<coding>
<system value="http://hl7.org/fhir/study-design"/>
<code value="SEVCO:01001"/>
<display value="Interventional research"/>
</coding>
</studyDesign>
<keyword>
<text value="Prostatic Cancer"/>
</keyword>
<keyword>
<text value="Family History"/>
</keyword>
<keyword>
<text value="Prostatic-Specific Antigen"/>
</keyword>
<keyword>
<text value="DRE"/>
</keyword>
<description
value="A study to evaluate the impact of family history on prostatic cancer follow-up criterias, such as level of prostatic-specific antigen and DRE."/>
<period>
<start value="2025-01-01"/>
<end value="2025-12-31"/>
</period>
<associatedParty>
<name value="Research Coordinator"/>
<role>
<coding>
<system value="http://hl7.org/fhir/research-study-party-role"/>
<code value="general-contact"/>
</coding>
</role>
</associatedParty>
<recruitment>
<eligibility>🔗
<reference value="EvidenceVariable/EV-InclusionCriteriaFLUTE"/>
<identifier>
<system value="https://flute.com/EvidenceVariable"/>
<value value="FLUTEInclusionVariable"/>
</identifier>
</eligibility>
</recruitment>
</ResearchStudy>